were evaluated for antiviral activities against human cytomegalovirus (HCMV) and compared with 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) and E-5-(2'-bromovinyl)-2'-deoxyuridine (BVDU). The relative anti-HCMV potencies of these compounds, as determined by calculating the dose of drug which inhibited 50% plaque formation, were in order of decreasing potency: FIAC > FIAU > FMAU > acyclovir > FEAU > BVDU. The antiviral activity of FIAC occurred at levels much lower than those that caused cytotoxic or cytostatic effects in uninfected fibroblasts. Neither thymidine nor deoxycytidine reversed the anti-HCMV activity of FIAC, indicating that this drug was not acting as an analog of the natural nucleosides. FIAC was not phosphorylated by cytosols of HCMV-infected cells to a greater extent that by those of uninfected cells, indicating that, unlike the antiviral activity against herpes simplex virus type 1, the selectivity of this drug is probably not based on a virus-specified pyrimidine kinase.
With the advent of aggressive immunosuppression for renal transplantation (1), bone marrow transplantation (19) , and, more recently, heart transplantation (20) has come the recognition that human cytomegalovirus (HCMV) can cause life-threatening infections and is a major impediment to successful use of these treatments. In addition, HCMV has been associated with Kaposi's sarcoma, a malignancy which until recently was found only in older men in the United States (9) , but which has been detected during the past 4 years in male homosexuals with acquired immunodeficiency syndrome (12) . Recognition of HCMV as an important human pathogen has resulted in attempts to develop new chemotherapeutic agents for treatment of infections which it produces or with which it is associated. In this communication, we present evidence that one newly developed nucleoside analog has potent and selective activity against HCMV and that this activity is clearly different from that against herpes simplex virus type 1.
MATERIALS AND METHODS
Unlabeled and [2- Cultures of primary human foreskin fibroblasts were started in this laboratory and used for no more than 10 passages. Cells were routinely checked for mycoplasma contamination (22) . Monolayers of the fibroblasts were grown to about 80% confluency in 150-cm2 flasks for routine subculture of HCMV. Strain AD169 was obtained from the American Type Culture Collection and was used for most of these studies. Some experiments were carried out with HCMV strain 303, isolated from the urine of a child with a perinatal infection (Lopez, unpublished data (5). Very few dead cells were found, indicating that the reduced cell number was the result of cytostasis rather than cytotoxicity.
Cell cytosols were prepared for evaluation of pyrimidine kinase activity by the procedure of Kit et disks. The disks were washed twice with 15 ml of 1 mM ammonium formate, twice with 15 ml of distilled water, and once with 5 ml of 95% ethanol. The disks were then transferred to scintillation vials with 1 ml of 0.2 M KCI in 0.1 N HCI, and 10 ml of Biofluor (New England Nuclear Corp., Boston, Mass.) was added. The samples were refrigerated in the dark for 18 h before being counted. Table 1 sunmmarizes the results obtained in five experiments evaluating FIAC, FMAU, FIAU, ACV, and BVDU in the plaque reduction assay with HCMV and in a sensitive cytotoxicity assay with the same fibroblasts used in the plaque reductiqn assay. Only FIAC, FIAU, and FMAU consistently reduced plaque formation at drug concentrations below 1 ,uM. In most experiments, HCMV strain AD169 was used, but these drugs also were active with a recently isolated strain designated 303. In parallel experiments, however, two of these compounds FIAU and FMAU, demonstrated cytotoxicity with fibroblasts at levels equal to or below those showing antiviral effects. This cytotoxicity assay is very sensitive and yielded 50%o inhibitory doses, which were lower than those published for ACV (6) and BVDU (4). Only FIAC demonstrated truly selective antiviral activity since it was active against HCMV at 1/13 of the concentration required to inhibit the cell replication. Addition of tetrahydrouridine, a deoxycytidine deaminase inhibitor, to either the cytotoxicity assay or to the plaque reduction assay failed to alter significantly these results, indicating that the active component in each assay was FIAC and not FIAU, its deamination product (data not shown).
RESULTS
We tried to determine whether FIAC was acting as an analog for one of the natural nucleosides by using them to block the antiviral activity of this compound. Addition of equimolar concentrations of thymidine failed to reverse the antiviral activity and had no significant effect on the cytotoxicity (data not shown). A 10-fold excess of the thymidine failed to reverse the antiviral activity of FIAC and at higher concen- Our earlier studies showed that herpes simplex virus type 1-induced pyrimidine nucleoside kinase was capable of phosphorylating FIAC far better than the cellular enzymes and that this substrate preference determined, at least in part, the selective antiviral activity of this drug (18) . Studies were therefore undertaken to determine whether FIAC is preferentially phosphorylated by enzymes found in cytosols from HCMVinfected rather than uninfected cells. As others have noted (7, 14) , we found that HCMV infection offibroblasts resulted in a marked (up to 10-fold increase in thymidine kinase activity (data not shown). In addition, we found a slightly (twofold at most) increased deoxycytidine kinase activity in HCMV-infected cells (data not shown). Figure 1 presents the results of a typical experiment. Although both FIAC and FIAU were preferentially phosphorylated by enzymes found in herpes simplex virus type 1 cytosols, neither was preferentially activated by HCMV cytosols.
DISCUSSION
Infection of permissive cells by members of the herpesvirus group of viruses results in the expression in these cells of certain virally coded enzymes which have functions identical to those found in the uninfected cells but which differ in physical and chemical properties (3, 13, 15) . Two of these enzymes, a pyrimidine nucleoside kinase and a DNA polymerase (3, 10) , have been shown to have substrate specificities different from that of the normal cellular enzyme and have been employed as targets for the development of selective antiviral drugs. Studies with ACV, BVDU, and FIAC have strongly suggested that these compounds have selective activity against herpes simplex virus type 1 and herpes zoster virus because of the preferential phosphorylation of these compounds by the virally specified pyrimidine nucleoside kinase and, perhaps also because of a preferential interaction with the virally specified DNA polymerase (4, 8) . Although HCMV is a member of the herpesvirus group of viruses, the studies of Estes and Huang (7) have shown that infection with this virus fails to induce a new pyrimidine nucleoside kinase. Others have shown that HCMV infection results in a virally specified DNA polymerase (10, 11) .
The studies presented herein clearly demonstrate that FIAC, FMAU, and FIAU are potent inhibitors of HCMV replication in culture. Furthermore, FIAC activity appears to be selective in that it inhibited plaque formation at concen- trations of drug which were not cytotoxic or cytostatic. The cytotoxicity assay used here is very sensitive but was used to determine whether an effect on the cellular metabolism might be responsible for the antiviral effects found. Since selectivity was only found with FIAC, the antiviral effects of the other compounds might be a result of an effect of the drug on a metabolic step in the cell which is essential for viral replication.
Our observation that FIAC selectively inhibits HCMV plaque formation suggests that it may act on a viral metabolic step either not shared by the uninfected cell or not as sensitive in it. Although FIAC is not selectively phosphorylated in HCMV-infected cells, enough of the drug may be converted to the triphosphate by cellular enzymes to selectively inhibit the viral DNA polymerase. Alternatively, FIAC may act by a mechanism which does not require that it be phosphorylated in HCMV-infected cells. In similar studies, Bumns et al. (2) showed that ACV inhibits mouse cytomegalovirus replication without being phosphorylated selectively in infected cells. In preliminary studies, we found VOL. 24, 1983 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from that FIAC fails to be incorporated into HCMV DNA (Colacino and Lopez, unpublished data) again suggesting that its mechanism of action differs qualitatively from that found for herpes simplex virus type 1.
The selective activity of FIAC against HCMV suggests that it may be a candidate for clinical trials with this virus in humans. Since there appear to be no other clinically useful antiviral compounds which demonstrate selective activity against HCMV, an understanding of its mechanism of action will be important to our development of other drugs with perhaps. even greater selective activity. 
